Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.

ABSTRACT:

Background

Neoadjuvant platinum-based chemotherapy offers a modest survival advantage in muscle-invasive bladder cancer (MIBC) for patients with pathologic response. B7-H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial-cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum-based chemotherapy.

Methods

This was a retrospective cohort study among MIBC patients receiving neoadjuvant platinum-based chemotherapy followed by radical cystectomy. All patients underwent routine preoperative biopsy of their tumour. Immunohistochemistry was used to evaluate B7-H3 expre

SUBMITTER: Deol ES 

PROVIDER: S-EPMC11557263 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature